Biotechnology

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

A new campaign aims to save a major research hub, igniting a debate over its economic benefits, medical breakthroughs, and the future of animal testing.

Anika Therapeutics posts strong Q1 results with a 13% revenue jump, but analyst caution lingers over pipeline risks and long-term sustainability.

MindBio's new tech detects intoxication from your voice, promising safer workplaces but sparking major debate over surveillance, bias, and data privacy.

Scottish biotech EnteroBiotix secures major funding to advance its gut therapy for IBS-C, offering new hope for a disease-modifying treatment.

A first-in-class drug, NTX-2001, is now in human trials for alcohol use disorder, offering a new mechanism of action in a field with few options.

HitGen Inc.'s latest sustainability report signals a deep integration of ESG, leveraging its AI-driven R&D platform for both health and environmental gains.

Henlius and Organon's POHERDY gains EC approval, set to expand access and lower costs for a critical breast cancer therapy across the European Union.

A novel topical gel that boosts cellular energy is now in late-stage trials, offering new hope for healing the chronic wounds of diabetic foot ulcers.

New MD Andreas Goppelt brings a bold M&A and digital transformation agenda to OrphaCare, aiming to reshape rare disease patient care globally.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

YPrime's new AI Calculation Engine lets researchers use plain language to build complex trial logic, aiming to slash setup times and boost data accuracy.

A new partnership brings sustainable, wash-free lab tech to the GCC & MENA, aiming to accelerate drug discovery in the world's fastest-growing life-science market.

A Dubai hospital pioneers a one-time gene therapy for an adult with SMA, offering new hope to a patient population previously left with limited options.

A new cell-free therapy, Ultrasome™, shows a 93% response rate in a pilot study, offering a scalable, regenerative solution for millions with knee pain.

Vensica Medical gets FDA clearance for a Phase 2 study of its ultrasound device that delivers botulinum toxin without needles for overactive bladder.

Neurogene bets on a direct-to-brain delivery method for its Rett syndrome gene therapy, arguing the established surgical technique offers superior results.

Kiniksa raises its 2026 ARCALYST forecast after a blowout quarter, using its financial strength to advance a pipeline aimed at redefining pericarditis care.

With a massive Series A, Coultreon Biopharma is advancing a novel SIK3 inhibitor spun out of Galapagos to rival injectable blockbusters for autoimmune disease.